MedPath

Efficacy of Sharapunkhadi yoga and life style modification in the management of Non Alcoholic Fatty Liver Disease

Phase 4
Completed
Conditions
Health Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: null- USG findings suggestive of NAFLD Grade I, II & III
Registration Number
CTRI/2016/02/006623
Lead Sponsor
IPGT AND RA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
93
Inclusion Criteria

Patients of either sex of age group above 25 yrs and below 60yrs

USG findings suggestive of Non Alcoholic Fatty Liver Disease grade I II III

Both freshly detected and previously diagnosed cases of NAFLD

Exclusion Criteria

Patient aged below 25 years and above 60 years pregnant ladies

Patients with uncontrolled diabetes or hypertension

Patients with complications of Metabolic syndrome like Cerebrovascular accident Myocardial Infarction Chronic Kidney disease

Patients consuming hepatotoxic medicines alcohol or other narcotic substances

Patients suffering from Cirrhosis Ascites variceal haemorrhage coagulopathy hepato renal syndrome

Patients having history of viral hepatitis auto immune liver diseases like Primary biliary cirrhosis primary sclerosing cholangitis autoimmune hepatitis metabolic disorders like Wilsons disease haemochromatosis

Patients suffering from HIV TB other infectious diseases malignancies major psychiatric problems or any other serious illnesses

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is expected that the trial drug will normalize Liver Function tests and reverse fatty changes of liverTimepoint: 8 weeks
Secondary Outcome Measures
NameTimeMethod
By providing better effect on Non Alcoholic Fatty Liver Disease drug may reduce the risk of Non Alcoholic Steato Hepatitis Fibrosis Cirrhosis Ascites and further complications of end stage liver disease and thus improve quality of life.Timepoint: 8 weeks treatment and 4 weeks follow up
© Copyright 2025. All Rights Reserved by MedPath